By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut healing time by half and significantly improved healing outcomes compared to control treatments.
Results from the combination therapy, which was tested in mice, were published online today in Advances in Wound Care,
“Not only did wound healing occur more rapidly and completely, but actual regeneration occurred, with hair follicles and the skin’s supportive collagen network restored in wounded skin—clinically important improvements that are unprecedented in wound care,” says senior author David J. Sharp, Ph.D., professor of physiology & biophysics at Einstein. “We foresee this therapy having broad application for all sorts of wounds, from playground cuts to battlefield injuries to chronic wounds.”
Chronic wounds alone affect 6.5 million Americans and cost $25 billion in annual healthcare costs. Over the past several decades, few advances have been made in treating wounds of any type.
In 2015, Dr. Sharp and colleagues discovered that an enzyme called fidgetin-like 2 (FL2) puts the brakes on skin cells as they migrate towards wounds to heal them. He reasoned that reducing FL2 levels might enable healing cells to reach their destination faster. So he and his colleagues developed small interfering RNA molecules (siRNAs) that specifically inhibit the gene that codes for FL2. When the siRNAs were encased in nanoparticles and sprayed on skin wounds in mice, the treated wounds healed faster than untreated wounds.
In the current study, Dr. Sharp enhanced the siRNAs’ wound-healing potential by combining them with PluroGel—a protective gel that keeps wounds moist and has antimicrobial properties when applied to bandages and other wound dressings. In addition, Dr. Sharp incorporated the siRNAs into microparticles made of collagen, a naturally occurring protein that readily releases its siRNA “cargo” after coming in contact with the skin.
The FL2-siRNA/PluroGel combination was applied to mice with either skin excisions or burns. For comparison, studies involving both types of skin injuries also used two control groups: mice treated with PluroGel alone and mice treated with PluroGel plus siRNA that did not target the gene for FL2. Wounds were treated on the day of the skin excision or burn and again two, four and six days later. For 14 days following the injuries, wounds were assessed by investigators who were “blinded” as to the treatment the mice received.
On the fourth day after mice treated for excision wounds, the open wound areas of mice in the two control groups were nearly twice as large as the wound areas in mice treated with the FL2-siRNA/PluroGel combination. Several mice treated with the combination therapy also had hair follicles present in the wound zone, while no such structures were seen in the control mice.
For mice treated for burns: by 14-days post injury, the wounds of mice in both control groups were more than one-third larger than in the mice treated with the FL2-siRNA/PluroGel combination. In addition, the burn wounds of all mice treated with the FL2-siRNA/PluroGel combination had closed completely by day 14; by comparison, 25 percent and 30 percent of treated wounds in the PluroGel and PluroGel/nontarget siRNA control groups, respectively, remained unhealed at that time.
“These results show that FL2-siRNA plus PluroGel is a highly promising wound treatment,” says Adam Kramer, a Ph.D. candidate in Dr. Sharp’s lab and co-lead author. “By lowering FL2 levels in skin cells, the FL2-siRNA helps cells reach wound sites much faster than they ordinarily would—essential for minimizing scarring and preventing wounds from becoming chronic. And by hydrating wounds and inhibiting microbes, PluroGel offers important additional wound-healing benefits.”
Dr. Sharp and Brian O’Rourke, Ph.D., the paper’s co-lead author and chief scientist at MicroCures, Inc., have achieved similar success in treating skin wounds in pigs—animals with skin that closely resembles human skin. Dr. Sharp’s team plans to seek permission from the U.S. Food and Drug Administration to test their wound-healing therapy in clinical trials.
Learn more: Novel Combination Therapy Promotes Wound Healing
The Latest on: Combination therapy
via Google News
The Latest on: Combination therapy
- Combination therapy using malaria drug quickly clears TBon November 30, 2019 at 5:51 am
They have also demonstrated that a drug combination that prevents the bacteria from inducing this mechanism leads to almost complete clearance of the bacteria from the mice lungs in just two months of ...
- These abstract therapy dolls help kids recover from traumaon November 27, 2019 at 5:00 am
Additionally, the combination of the two main materials is designed to represent a balance between positive and negative experiences.” [Photo: courtesy Yaara Nusboim] Play therapy has been around for ...
- Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinomaon November 26, 2019 at 2:22 am
These data suggest that combination therapy with foretinib and lapatinib should be tested as a treatment option for HER2 positive patients with MET-overexpressing EAC, and could be a novel treatment ...
- Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japanon November 25, 2019 at 10:00 pm
In this trial, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor, biguanide, sulphonylurea, ...
- Combination therapy improves survival in patients with hepatocellular carcinomaon November 22, 2019 at 12:52 pm
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable ...
- Combination therapy may boost height for girls with central precocious pubertyon November 21, 2019 at 7:01 am
Chinese girls diagnosed with central precocious puberty achieved greater gains in total height when treated with combination gonadotropin-releasing hormone analogues, or GnRHa, plus recombinant growth ...
- Physical Therapy Not Just for Grown-Ups!on November 20, 2019 at 10:12 pm
So what can a patient actually expect from a typical session? Most physical therapy uses a combination of techniques to relieve pain and boost coordination, strength, endurance, flexibility, and range ...
- Pancreatic Tumors Succumb to Combination of Two Approved Drugson November 20, 2019 at 12:29 pm
“The sad reality is that at present, pancreatic cancer therapy is lagging since there is no effective ... “Our study identifies a potential treatment combination that can immediately be tested against ...
- Rochester cancer therapy firm to collaborate with drugment on melanoma treatmenton November 20, 2019 at 10:23 am
Libtayo is approved in the U.S., while Voyager-V1 is not. Voyager V1 is under investigation as a stand-alone cancer therapy as well as a combination therapy in multiple Phase 1 and Phase 2 clinical ...
via Bing News